In the Nov. 15, 1995, issue of BioWorld Today an articleon a new agreement between Japan-based SantenPharmaceuticals Co. Ltd. and Houston BiotechnologyInc., of The Woodlands, Texas, should have saidtermination of the companies' original collaboration wasunrelated to Houston Biotechnology's progress on thedrug development project.

CLARIFICATION

An article in the Nov. 15, 1995, issue of BioWorld Todayon cloning the Gaucher's disease enzyme,glucocerebrosidase, in a tobacco plant delivery systemelicited the following clarifications from Genzyme Corp.:

* The average cost of Ceredase is $150,000 per year.

* An estimate (made by CropTech Development Corp.'spresident) that 2,000 to 8,000 placentas are needed toproduce one dose of Ceredase is 10 times too high.

* Genzyme's recombinant glucocerebrosidase is alreadyon the market, and has orphan drug exclusivity until May2001.

(c) 1997 American Health Consultants. All rights reserved.